Matching articles for "cholesterol"
Issue 1759 · July 20, 2026
Drugs for Hypertriglyceridemia

Adults with persistent fasting triglyceride levels ≥150 mg/dL are considered to have hypertriglyceridemia; when levels are ≥500 mg/dL, it is considered severe. Hypertriglyceridemia is associated with an…

Med Lett Drugs Ther. 2026 Jul 20; 68(1759):117-9 doi:10.58347/tml.2026.1759e
Adults with persistent fasting triglyceride levels ≥150 mg/dL are considered to have hypertriglyceridemia; when levels are ≥500 mg/dL, it is considered severe. Hypertriglyceridemia is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD); severe hypertriglyceridemia increases the risk of acute pancreatitis.
Issue 1756 · June 8, 2026
Comparison Chart: Statins (online only)

View the Comparison Chart: Statins

Med Lett Drugs Ther. 2026 Jun 8; 68(1756):e94-5 doi:10.58347/tml.2026.1756b
View the Comparison Chart: Statins
Issue 1756 · June 8, 2026
Comparison Chart: Some Non-Statin Lipid-Lowering Drugs (online only)

View the Comparison Chart: Some Non-Statin Lipid-Lowering Drugs

Med Lett Drugs Ther. 2026 Jun 8; 68(1756):e96-8 doi:10.58347/tml.2026.1756c
View the Comparison Chart: Some Non-Statin Lipid-Lowering Drugs
Issue 1737 · September 15, 2025
Inclisiran (Leqvio) Monotherapy for LDL-Cholesterol Reduction

Inclisiran ( Leqvio – Novartis), a subcutaneously injected small interfering RNA (siRNA) that decreases LDL-cholesterol (LDL-C) levels by reducing synthesis of proprotein convertase subtilisin/kexin type 9…

Med Lett Drugs Ther. 2025 Sep 15; 67(1737):148-9 doi:10.58347/tml.2025.1737c
Inclisiran ( Leqvio – Novartis), a subcutaneously injected small interfering RNA (siRNA) that decreases LDL-cholesterol (LDL-C) levels by reducing synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), has been approved by the FDA for use with or without a statin to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Inclisiran had previously been approved for use only in combination with statin therapy.
Issue 1737 · September 15, 2025
Inclisiran (Leqvio) Monotherapy for LDL-Cholesterol Reduction

Inclisiran ( Leqvio – Novartis), a subcutaneously injected small interfering RNA (siRNA) that decreases LDL-cholesterol (LDL-C) levels by reducing synthesis of proprotein convertase subtilisin/kexin type 9…

Med Lett Drugs Ther. 2025 Sep 15; 67(1737):148-9 doi:10.58347/tml.2025.1737c
Inclisiran ( Leqvio – Novartis), a subcutaneously injected small interfering RNA (siRNA) that decreases LDL-cholesterol (LDL-C) levels by reducing synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), has been approved by the FDA for use with or without a statin to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Inclisiran had previously been approved for use only in combination with statin therapy.
Issue 1674 · April 17, 2023 Free
In Brief: Cardiovascular Outcomes with Bempedoic Acid (Nexletol)

Since our initial review of the oral lipid-lowering adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid ( Nexletol – Esperion) in 2020, cardiovascular outcomes data in statin-intolerant…

Med Lett Drugs Ther. 2023 Apr 17; 65(1674):62-3 doi:10.58347/tml.2023.1674b
Since our initial review of the oral lipid-lowering adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid ( Nexletol – Esperion) in 2020, cardiovascular outcomes data in statin-intolerant patients have become available.
Issue 1659 · September 19, 2022
Comparison Table: Some Lipid-Lowering Drugs (online only)

View the Comparison Table: Some Lipid-Lowering Drugs

Med Lett Drugs Ther. 2022 Sep 19; 64(1659):e152-6
View the Comparison Table: Some Lipid-Lowering Drugs
Issue 1595 · April 6, 2020
Bempedoic Acid (Nexletol) for Lowering LDL-Cholesterol

The FDA has approved the oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid for use alone ( Nexletol – Esperion) and in a fixed-dose combination with the cholesterol absorption…

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):53-5
The FDA has approved the oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid for use alone ( Nexletol – Esperion) and in a fixed-dose combination with the cholesterol absorption inhibitor ezetimibe (Nexlizet) as an adjunct to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-cholesterol (LDL-C). Bempedoic acid is the first ACL inhibitor to be approved in the US.
Issue 1591 · February 10, 2020
Reduction of Cardiovascular Risk with Icosapent Ethyl (Vascepa)

Icosapent ethyl ( Vascepa – Amarin), the ethyl ester of eicosapentaenoic acid (EPA), has been approved by the FDA for use as an adjunct to maximally tolerated statin therapy to reduce the risk of major…

Med Lett Drugs Ther. 2020 Feb 10; 62(1591):17-8
Icosapent ethyl ( Vascepa – Amarin), the ethyl ester of eicosapentaenoic acid (EPA), has been approved by the FDA for use as an adjunct to maximally tolerated statin therapy to reduce the risk of major adverse cardiovascular events in adults with hypertriglyceridemia (≥150 mg/dL) who have either established cardiovascular disease (CVD) or diabetes and ≥2 additional risk factors for CVD. It is the only omega-3 polyunsaturated fatty acid (PUFA) product to be approved in the US for this indication. Icosapent ethyl and two other omega-3 PUFA prescription products (Lovaza, Epanova) , which contain both EPA and docosahexaenoic acid (DHA), were approved earlier for treatment of severe hypertriglyceridemia (≥500 mg/dL).
Issue 1585 · November 18, 2019
Turmeric Supplements

Turmeric is a spice derived from the Curcuma longa plant. Dietary supplements and foods containing turmeric are widely promoted for relief of pain and to improve joint mobility, immunity, digestion,…

Med Lett Drugs Ther. 2019 Nov 18; 61(1585):185
Turmeric is a spice derived from the Curcuma longa plant. Dietary supplements and foods containing turmeric are widely promoted for relief of pain and to improve joint mobility, immunity, digestion, cardiovascular health, depression, anxiety, memory, and cognition.
Issue 1565 · February 11, 2019
Lipid-Lowering Drugs

Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force have recently been published. See Table 1 for a brief summary of their recommendations.

Med Lett Drugs Ther. 2019 Feb 11; 61(1565):17-24
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force have recently been published. See Table 1 for a brief summary of their recommendations.
Issue 1565 · February 11, 2019
Expanded Table: Lipid-Lowering Drugs (online only)

View the Expanded Table: Lipid-Lowering Drugs

Med Lett Drugs Ther. 2019 Feb 11; 61(1565):e24-30
View the Expanded Table: Lipid-Lowering Drugs
Issue 1549 · June 18, 2018 Free
In Brief: Pitavastatin Magnesium (Zypitamag) for Hyperlipidemia

The FDA has approved the HMG-CoA reductase inhibitor (statin) pitavastatin magnesium ( Zypitamag – Zydus) for use in adults with primary hyperlipidemia or mixed dyslipidemia. The FDA considers pitavastatin…

Med Lett Drugs Ther. 2018 Jun 18; 60(1549):106
The FDA has approved the HMG-CoA reductase inhibitor (statin) pitavastatin magnesium ( Zypitamag – Zydus) for use in adults with primary hyperlipidemia or mixed dyslipidemia. The FDA considers pitavastatin magnesium bioequivalent to pitavastatin calcium (Livalo) , which was approved in 2009. 1 Statins remain the treatment of choice for most patients who require lipid-lowering therapy. Taken as an adjunct to diet modification, increased exercise, and smoking cessation, statins can reduce the risk of primary and secondary cardiovascular events and death in patients with or at high risk for atherosclerotic cardiovascular disease. 2 Even in patients at low risk for cardiovascular disease, treatment with a statin can significantly reduce the incidence of cardiovascular events. 3 Controlled trials in patients with cardiovascular disease have shown that high-intensity statin therapy (defined as reducing LDL-cholesterol [LDL-C] by ≥50% on average) reduces the incidence of cardiac events, stroke, and coronary death significantly more than less intensive regimens. In one meta-analysis, each additional 1 mmol/L (39 mg/dL) reduction in LDL-C was associated with a 20% reduction in major vascular events and a 10% reduction in all-cause mortality. 4 In a randomized trial in 13,054 Japanese patients with stable coronary artery disease, over a median follow-up of 3.9 years, patients taking pitavastatin calcium 4 mg daily were significantly less likely than those taking 1 mg daily to have a cardiovascular event (4.3% vs 5.4%). 5 Approval of pitavastatin magnesium was based on the results of trials with pitavastatin calcium; no new efficacy trials were required. The Medical Letter's review of pitavastatin calcium concluded that recommended doses of the drug had not been shown to decrease LDL-C more than other statins with longer safety records and there was no good reason to use it. That conclusion applies to pitavastatin magnesium as well. Pitavastatin (Livalo) – the seventh statin. Med Lett Drugs Ther 2010; 52:57. Lipid-lowering drugs. Med Lett Drugs Ther 2016; 58:133. CTT Collaboration et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380:581. CTT Collaboration et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670. I Taguchi et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation 2018; 137:1997. Download complete U.S. English article
Issue 1509 · December 5, 2016 Free
Addendum: Statins for Primary Prevention of Cardiovascular Disease

In our recent article on Lipid-Lowering Drugs, 1 we said that statins can reduce the risk of first cardiovascular events and death (primary prevention) in patients at high risk for atherosclerotic…

Med Lett Drugs Ther. 2016 Dec 5; 58(1509):158
In our recent article on Lipid-Lowering Drugs, 1 we said that statins can reduce the risk of first cardiovascular events and death (primary prevention) in patients at high risk for atherosclerotic cardiovascular disease (CVD) and significantly reduce the incidence of cardiovascular events in patients at lower risk for CVD. Now the United States Preventive Services Task Force (USPSTF) has issued new recommendations on the appropriate use of statins for primary prevention of CVD. 2 The USPSTF states that clinicians should periodically screen all persons 40-75 years old for cardiovascular risk factors and evaluate their 10-year risk of CVD using the ACC/AHA Pooled Cohort Equation. 3 It recommends starting low- to moderate-intensity statin therapy (lowintensity statin therapy lowers LDL-cholesterol <30%; moderate-intensity statin therapy lowers it 30-<50%) in adults 40-75 years old without CVD who have one or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD event risk of >10%. For patients with the same characteristics but a 7.5-10% 10-year risk, the USPSTF recommends that clinicians "selectively offer" the same treatment. The new recommendations do not apply to patients with familial hypercholesterolemia or LDL-cholesterol levels ≥190 mg/dL, who should take a statin regardless of calculated risk. The USPSTF found the evidence insufficient to recommend starting a statin for primary prevention in persons >75 years old. Lipid-lowering drugs. Med Lett Drugs Ther 2016; 58:133. US Preventive Services Task Force et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA 2016; 316:1997. American Heart Association and American College of Cardiology. ASCVD Risk Estimator. Available at: tools.acc.org. Accessed November 22, 2016. Download complete U.S. English article
Issue 1506 · October 24, 2016
Lipid-Lowering Drugs

Lipid-lowering drugs should be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels. HMG-CoA reductase inhibitors (statins) remain the drugs of choice for treatment of…

Med Lett Drugs Ther. 2016 Oct 24; 58(1506):133-40
Lipid-lowering drugs should be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels. HMG-CoA reductase inhibitors (statins) remain the drugs of choice for treatment of most patients who require lipid-lowering therapy.
Issue 1457 · December 8, 2014 Free
In Brief: Adding Ezetimibe to a Statin Improves Clinical Outcomes

Combining a statin with another drug that lowers low-density lipoprotein cholesterol (LDL-C), such as colesevelam (Welchol) , niacin ( Niaspan , and others), or ezetimibe (Zetia) , can reduce LDL-C levels more…

Med Lett Drugs Ther. 2014 Dec 8; 56(1457):126
Combining a statin with another drug that lowers low-density lipoprotein cholesterol (LDL-C), such as colesevelam (Welchol) , niacin ( Niaspan , and others), or ezetimibe (Zetia) , can reduce LDL-C levels more than a statin alone, but studies convincingly demonstrating that such combinations improve clinical outcomes have been lacking. The results of a long-term randomized, double-blind clinical trial (IMPROVE-IT) recently presented at the American Heart Association's Scientific Sessions 2014 indicate that addition of ezetimibe to simvastatin in high-risk patients reduces cardiovascular events. 1 IMPROVE-IT compared the efficacy of simvastatin 40 mg plus placebo with that of simvastatin 40 mg plus ezetimibe 10 mg (Vytorin) in preventing the primary endpoint, a composite of cardiovascular events (cardiovascular death, MI, hospital admission for unstable angina, coronary revascularization, or stroke) in patients with acute coronary syndrome and normal LDL-C levels (≤125 mg/dL; mean 95 mg/dL). After one year, mean LDL-C was reduced further with the addition of ezetimibe (to 53.2 vs. 69.9 mg/dL with simvastatin alone). After 7 years, 2742 events had occurred among the 9077 patients taking simvastatin plus placebo and 2572 among the 9067 taking simvastatin plus ezetimibe (event rate: 34.7% vs. 32.7%; p = 0.016). There was no significant difference between the 2 groups in noncardiovascular adverse events, including gallbladder-related events, myopathy, or cancer. C Cannon et al. IMProved Reduction of Outcomes: Vytorin Efficacy International Trial. Available at www.timi.org. Accessed November 21, 2014. Download complete U.S. English article
Issue 137 · January 1, 2014
Drugs for Lipids

HMG-CoA reductase inhibitors (statins) inhibit the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. The subsequent reduction in hepatic cholesterol leads to increased expression of LDL…

Treat Guidel Med Lett. 2014 Jan; 12(137):1-6
HMG-CoA reductase inhibitors (statins) inhibit the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. The subsequent reduction in hepatic cholesterol leads to increased expression of LDL receptors, which in turn increases uptake and clearance of LDL-C from the blood. Statins also lower very low-density lipoprotein cholesterol (VLDL-C) and triglycerides. Most statins increase high-density lipoprotein cholesterol (HDL-C), but only modestly.
Issue 1419 · June 24, 2013
Liptruzet: A Combination of Ezetimibe and Atorvastatin

The FDA has approved a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe and the HMG-CoA reductase inhibitor (statin) atorvastatin as Liptruzet (Merck) for treatment of hyperlipidemia.…

Med Lett Drugs Ther. 2013 Jun 24; 55(1419):49-50
The FDA has approved a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe and the HMG-CoA reductase inhibitor (statin) atorvastatin as Liptruzet (Merck) for treatment of hyperlipidemia. Ezetimibe is also available in a fixed-dose combination with simvastatin (Vytorin) .
Issue 1415 · April 29, 2013
Icosapent Ethyl (Vascepa) for Severe Hypertriglyceridemia

Icosapent ethyl ( Vascepa [vas EE puh] – Amarin), the ethyl ester of eicosapentaenoic acid (EPA), has been approved by the FDA as an adjunct to diet for treatment of severe hypertriglyceridemia (≥500…

Med Lett Drugs Ther. 2013 Apr 29; 55(1415):33-4
Icosapent ethyl ( Vascepa [vas EE puh] – Amarin), the ethyl ester of eicosapentaenoic acid (EPA), has been approved by the FDA as an adjunct to diet for treatment of severe hypertriglyceridemia (≥500 mg/dL). Vascepa is the second omega-3 polyunsaturated fatty acid (PUFA) product to become available by prescription for this indication; Lovaza (formerly Omacor ), which is a combination of the ethyl esters of EPA and docosahexaenoic acid (DHA), was the first. Many omega-3 PUFA-containing fish oil capsules are sold over the counter as dietary supplements.
Issue 1413 · April 1, 2013
Two New Drugs for Homozygous Familial Hypercholesterolemia

The FDA has approved mipomersen ( Kynamro – Genzyme) and lomitapide ( Juxtapid – Aegerion), each in addition to a low-fat diet and other lipid-lowering medications, to reduce cholesterol levels in patients…

Med Lett Drugs Ther. 2013 Apr 1; 55(1413):25-7
The FDA has approved mipomersen ( Kynamro – Genzyme) and lomitapide ( Juxtapid – Aegerion), each in addition to a low-fat diet and other lipid-lowering medications, to reduce cholesterol levels in patients with homozygous familial hypercholesterolemia (HoFH).
Issue 1411 · March 4, 2013
Drugs for Hypertriglyceridemia

Fibrates, niacin and fish oil are promoted for treatment of hypertriglyceridemia. HMG-CoA reductase inhibitors (statins) can lower elevated serum concentrations of triglycerides, but less so than fibrates,…

Med Lett Drugs Ther. 2013 Mar 4; 55(1411):17-9
Fibrates, niacin and fish oil are promoted for treatment of hypertriglyceridemia. HMG-CoA reductase inhibitors (statins) can lower elevated serum concentrations of triglycerides, but less so than fibrates, niacins or fish oil. Lifestyle changes such as weight reduction, exercise and decreasing alcohol intake can also lower serum triglyceride levels and should be tried first.
Issue 1378 · November 28, 2011
What about Niacin?

The results of the AIM-HIGH trial conducted by the US National Heart, Lung and Blood Institute (NHLBI) were recently published. The goal of the trial was to test whether addition of niacin to intensive statin…

Med Lett Drugs Ther. 2011 Nov 28; 53(1378):93-4
The results of the AIM-HIGH trial conducted by the US National Heart, Lung and Blood Institute (NHLBI) were recently published. The goal of the trial was to test whether addition of niacin to intensive statin therapy would further reduce the risk of cardiovascular disease. The trial was stopped prematurely after an average follow-up of 3 years because niacin therapy had not shown any clinical benefit.
Issue 1377 · November 14, 2011
Sitagliptin and Simvastatin (Juvisync)

The FDA has approved Juvisync (Merck), a fixed-dose combination of the antihyperglycemic DPP-4 inhibitor sitagliptin (Januvia) and the HMG-CoA reductase inhibitor simvastatin ( Zocor , and others).

Med Lett Drugs Ther. 2011 Nov 14; 53(1377):89
The FDA has approved Juvisync (Merck), a fixed-dose combination of the antihyperglycemic DPP-4 inhibitor sitagliptin (Januvia) and the HMG-CoA reductase inhibitor simvastatin ( Zocor , and others).
Issue 103 · March 1, 2011
Drugs for Lipids

Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. Lipid-regulating drugs must be taken…

Treat Guidel Med Lett. 2011 Mar; 9(103):13-20
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels in 2-3 weeks.
Issue 1343 · July 26, 2010
Pitavastatin (Livalo) - The Seventh Statin

The FDA has approved the marketing of pitavastatin ( Livalo – Kowa), an HMG-CoA reductase inhibitor (“statin”), for treatment of primary hyperlipidemia or mixed dyslipidemia. It has been available in…

Med Lett Drugs Ther. 2010 Jul 26; 52(1343):57-8
The FDA has approved the marketing of pitavastatin ( Livalo – Kowa), an HMG-CoA reductase inhibitor (“statin”), for treatment of primary hyperlipidemia or mixed dyslipidemia. It has been available in Japan since 2003. All of the statins now available in the US are listed in the table on page 58.
Issue 1320 · September 7, 2009
Red Yeast Rice

Red yeast rice is a food product that has been used in Chinese cooking and medicine for centuries. It is available in the US in a capsule formulation and is often used by patients who want a "natural" product…

Med Lett Drugs Ther. 2009 Sep 7; 51(1320):71-2
Red yeast rice is a food product that has been used in Chinese cooking and medicine for centuries. It is available in the US in a capsule formulation and is often used by patients who want a "natural" product to lower cholesterol.
Issue 1317 · July 27, 2009
When a Statin Fails

The National Cholesterol Education Program recommends that LDL-C be lowered to less than 100 mg/dL (2.6 mmol/L) and considers a value <70 mg/dL (1.8 mmol/L) a reasonable goal for patients at very high risk.

Med Lett Drugs Ther. 2009 Jul 27; 51(1317):58-60
The National Cholesterol Education Program recommends that LDL-C be lowered to less than 100 mg/dL (2.6 mmol/L) and considers a value <70 mg/dL (1.8 mmol/L) a reasonable goal for patients at very high risk.
Issue 1297 · October 20, 2008
Drug Interactions with Simvastatin

A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin ( Zocor , and others) and green tea. Since it became…

Med Lett Drugs Ther. 2008 Oct 20; 50(1297):83-4
A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin ( Zocor , and others) and green tea. Since it became available generically, simvastatin has surpassed atorvastatin ( Lipitor ) as the best selling statin. As such, it is probably the most common cause of statin-induced myopathy, which is often a result of drug interactions.
Issue 1293 · August 25, 2008
Ezetimibe Revisited

In recent months, both the lay media and some medical experts have raised concerns about the effectiveness and safety of ezetimibe, a widely used drug that prevents absorption of cholesterol from the GI tract.…

Med Lett Drugs Ther. 2008 Aug 25; 50(1293):67-8
In recent months, both the lay media and some medical experts have raised concerns about the effectiveness and safety of ezetimibe, a widely used drug that prevents absorption of cholesterol from the GI tract. Ezetimibe is available alone as Zetia and in combination with 10, 20, 40 and 80 mg of simvastatin ( Zocor , and others) as Vytorin .
Issue 1285 · May 5, 2008 Free
In Brief: A New Indication for Colesevelam (Welchol)

Colesevelam ( Welchol - Daiichi Sankyo - Med Lett Drugs Ther 2000; 42:102 ), a bile-acid sequestrant used to lower LDL cholesterol, has been approved by the FDA as an adjunct to diet and exercise in the…

Med Lett Drugs Ther. 2008 May 5; 50(1285):33
Colesevelam ( Welchol - Daiichi Sankyo - Med Lett Drugs Ther 2000; 42:102 ), a bile-acid sequestrant used to lower LDL cholesterol, has been approved by the FDA as an adjunct to diet and exercise in the treatment of type 2 diabetes. In unpublished studies summarized in the package insert, patients with type 2 diabetes taking metformin ( Glucophage , and others), a sulfonylurea or insulin (each as either monotherapy or in combination with other anti-diabetic agents) were given colesevelam 3800 mg per day or placebo; colesevelam significantly reduced glycosylated hemoglobin (A1c) by about 0.5% more than placebo in all three trials. The mechanism is unclear. Colesevelam can cause constipation, nausea and dyspepsia, increase serum triglyceride concentrations, and interfere with absorption of other oral drugs. One month's treatment with Welchol obtained from drugstore.com would cost about $200. Medical Letter consultants are not enthusiastic about prescribing it for this indication. Download U.S. English
Issue 1284 · April 21, 2008
Which Statin?

Advertisements for atorvastatin (Lipitor) , the market leader facing generic competition, have been in the news recently in the US. Lovastatin, pravastatin and simvastatin are all available generically at a…

Med Lett Drugs Ther. 2008 Apr 21; 50(1284):29-31
Advertisements for atorvastatin (Lipitor) , the market leader facing generic competition, have been in the news recently in the US. Lovastatin, pravastatin and simvastatin are all available generically at a much lower retail price or lower co-pay than atorvastatin.
Issue 66 · February 1, 2008
Drugs for Lipids

Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. They should not be used as a substitute for…

Treat Guidel Med Lett. 2008 Feb; 6(66):9-16
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. They should not be used as a substitute for lifestyle changes; a combination of diet, exercise and lipid-lowering drugs is optimal for prevention of coronary disease. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipoprotein levels return to pretreatment levels in 2-3 weeks.
Issue 1267 · August 13, 2007
Reducing Intake of Trans Fatty Acids

The New York City Board of Health has recently required that city restaurants reduce the content of industrially produced trans fatty acids so that each serving contains <0.5 g. This initiative is intended to…

Med Lett Drugs Ther. 2007 Aug 13; 49(1267):65-6
The New York City Board of Health has recently required that city restaurants reduce the content of industrially produced trans fatty acids so that each serving contains <0.5 g. This initiative is intended to reduce the number of coronary heart disease events in New York City. A more comprehensive approach used in Denmark since 2004 requires by law that fats and oils in all food contain <2% industrially produced trans fatty acids. The FDA requires that labels of packaged food include their trans fatty acid content. This requirement has led food manufacturers to develop brands containing zero or small amounts of trans fat.
Issue 1221 · November 7, 2005
Omega-3 Polyunsaturated Fatty Acids (Omacor) for Hypertriglyceridemia

A highly concentrated omega-3 polyunsaturated fatty acid (PUFA) preparation (Omacor - Reliant) has been approved by the FDA as an adjunct to diet for treatment of very high plasma triglyceride concentrations…

Med Lett Drugs Ther. 2005 Nov 7; 47(1221):91-2
A highly concentrated omega-3 polyunsaturated fatty acid (PUFA) preparation (Omacor - Reliant) has been approved by the FDA as an adjunct to diet for treatment of very high plasma triglyceride concentrations (>=500 mg/dL). Omacor is a combination of the ethyl esters of icosapentaenoic (EPA) and docosahexaenoic (DHA) acids. It is the first drug derived from omega-3 PUFAs to be sold by prescription.
Issue 1208 · May 9, 2005
Dehydroepiandrosterone (DHEA)

Dehydroepiandrosterone (DHEA), an endogenous adrenal steroid, is marketed as a dietary supplement in the US. It is widely promoted to reverse the effects of aging (loss of muscle, memory and libido) and has…

Med Lett Drugs Ther. 2005 May 9; 47(1208):37-8
Dehydroepiandrosterone (DHEA), an endogenous adrenal steroid, is marketed as a dietary supplement in the US. It is widely promoted to reverse the effects of aging (loss of muscle, memory and libido) and has been used by athletes as a substitute for anabolic steroids. DHEA is banned by the International Olympic Committee, National Collegiate Athletic Association, National Football League and other sports organizations, but it was specifically exempted from becoming a controlled substance in the Anabolic Steroid Control Act of 2004.
Issue 31 · March 1, 2005
Drugs for Lipids

Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. In controlled trials in patients with…

Treat Guidel Med Lett. 2005 Mar; 3(31):15-22
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. In controlled trials in patients with coronary disease, some of these drugs have reduced mortality by 20% to 30%.
Issue 1203 · February 28, 2005 Free
In Brief: Rhabdomyolysis with Ezetimibe

Health Canada, the Canadian equivalent of the FDA, recently issued a public advisory about postmarketing reports of myalgia, rhabdomyolysis, hepatitis, pancreatitis and thrombocytopenia associated with use of…

Med Lett Drugs Ther. 2005 Feb 28; 47(1203):17
Health Canada, the Canadian equivalent of the FDA, recently issued a public advisory about postmarketing reports of myalgia, rhabdomyolysis, hepatitis, pancreatitis and thrombocytopenia associated with use of ezetimibe ( Zetia in the US; Ezetrol in Canada). Ezetimibe is often added to a statin to increase LDL cholesterol lowering (Drugs for Lipids, Treat Guidel Med Lett 2005; 3:15) . The advisory did not specify whether these patients were also taking a statin, but according to the Canadian manufacturer Merck Frosst/Schering (Merck/Schering-Plough in the US), some of the patients who developed rhabdomyolysis were taking ezetimibe without a statin. In the US, ezetimibe is also available in a combination with simvastatin ( Vytorin - Med Lett Drugs Ther 2004; 46:73) . Recently, a few patients already taking a statin developed myalgia when ezetimibe was added (R Fux et al, Ann Intern Med 2004; 140:671) . The possibility that adding ezetimibe to a statin could increase the risk of rhabdomyolysis should be kept in mind.
Issue 1196 · November 22, 2004
Safety of Aggressive Statin Therapy

New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high…

Med Lett Drugs Ther. 2004 Nov 22; 46(1196):93-5
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Issue 1191 · September 13, 2004
Vytorin: A Combination of Ezetimibe and Simvastatin

Vytorin, a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe ( Zetia - Merck/Schering Plough) and the HMG-CoA reductase inhibitor ("statin") simvastatin ( Zocor - Merck), has been…

Med Lett Drugs Ther. 2004 Sep 13; 46(1191):73-4
Vytorin, a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe ( Zetia - Merck/Schering Plough) and the HMG-CoA reductase inhibitor ("statin") simvastatin ( Zocor - Merck), has been approved by the FDA for treatment of hypercholesterolemia. It is available as tablets containing 10 mg of ezetimibe combined with 10, 20, 40 or 80 mg of simvastatin.
Issue 1186 · July 5, 2004
Amlodipine/Atorvastatin (Caduet)

Caduet (Pfizer), a combination of the calcium-channel blocker amlodipine ( Norvasc - Pfizer) and the HMG-CoA reductase inhibitor (statin) atorvastatin ( Lipitor - Pfizer), is now available in the US. It was…

Med Lett Drugs Ther. 2004 Jul 5; 46(1186):56
Caduet (Pfizer), a combination of the calcium-channel blocker amlodipine ( Norvasc - Pfizer) and the HMG-CoA reductase inhibitor (statin) atorvastatin ( Lipitor - Pfizer), is now available in the US. It was approved by the FDA for use in patients with indications for treatment with both amlodipine, which is used to treat hypertension and/or angina pectoris, and atorvastatin, which is used to treat dyslipidemia. The combination is bioequivalent to the 2 components taken separately.
Issue 1182 · May 10, 2004
Cholesterol Rethink for High-Risk Patients

The recent "PROVE IT" trial in patients with coronary heart disease showed clinical benefits associated with reducing LDL cholesterol concentrations lower than the 100 mg/dL (2.59 mmol/L) or less that had been…

Med Lett Drugs Ther. 2004 May 10; 46(1182):37-9
The recent "PROVE IT" trial in patients with coronary heart disease showed clinical benefits associated with reducing LDL cholesterol concentrations lower than the 100 mg/dL (2.59 mmol/L) or less that had been considered optimal.
Issue 1167 · October 13, 2003
Rosuvastatin - a New Lipid-lowering Drug

Rosuvastatin ( Crestor - AstraZeneca), an HMG-CoA reductase inhibitor (or "statin"), was recently approved by the FDA for lowering serum cholesterol and triglyceride concentrations and raising HDL cholesterol…

Med Lett Drugs Ther. 2003 Oct 13; 45(1167):81-3
Rosuvastatin ( Crestor - AstraZeneca), an HMG-CoA reductase inhibitor (or "statin"), was recently approved by the FDA for lowering serum cholesterol and triglyceride concentrations and raising HDL cholesterol levels. Rosuvastatin, like other statins, inhibits the enzyme that catalyzes the rate-limiting step in cholesterol synthesis, but it is claimed to be more potent than the others. All of these drugs must be taken indefinitely; if they are discontinued, lipid levels return to baseline.
Issue 12 · August 1, 2003
Drugs For Lipid Disorders

Drugs that lower low-density lipoprotein (LDL) cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, and also improve vasodilatation. In controlled…

Treat Guidel Med Lett. 2003 Aug; 1(12):77-82
Drugs that lower low-density lipoprotein (LDL) cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, and also improve vasodilatation. In controlled trials in patients with coronary disease, they have reduced mortality by 30% to 40%. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipid levels return to pretreatment levels in 2-3 weeks.
Issue 1151 · March 3, 2003
Three New Drugs for Hyperlipidemia

The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia ) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol.…

Med Lett Drugs Ther. 2003 Mar 3; 45(1151):17-9
The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia ) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol. Extended-release lovastatin (Altocor) is a new formulation of lovastatin ( Mevacor , and others). Extended-release niacin plus (immediate-release) lovastatin (Advicor) is the first fixed-dose combination of lipid-lowering drugs.
Issue 1105 · May 28, 2001
Choice of Lipid-Regulating Drugs

New recommendations for drug treatment of hypercholesterolemia, if widely followed, will lead to a marked increase in the number of people taking lipid-regulating drugs.

Med Lett Drugs Ther. 2001 May 28; 43(1105):43-8
New recommendations for drug treatment of hypercholesterolemia, if widely followed, will lead to a marked increase in the number of people taking lipid-regulating drugs.
Issue 932 · September 30, 1994
Home Testing of Cholesterol

The new Advanced Care Cholesterol Test (Johnson & Johnson) now being advertised to the general public encourages patients to test their own serum cholesterol concentrations. Approved by the US Food and Drug…

Med Lett Drugs Ther. 1994 Sep 30; 36(932):85-6
The new Advanced Care Cholesterol Test (Johnson & Johnson) now being advertised to the general public encourages patients to test their own serum cholesterol concentrations. Approved by the US Food and Drug Administration, this product is available in pharmacies without a prescription at a cost of about $20 for a single determination.
Issue 923 · May 27, 1994
Fluvastatin for Lowering Cholesterol

Fluvastatin ( Lescol - Sandoz), an HMG-CoA reductase inhibitor, was recently marketed in the USA for treatment of hypercholesterolemia. A synthetic mevalonolactone derivative, it is chemically distinct from…

Med Lett Drugs Ther. 1994 May 27; 36(923):45-6
Fluvastatin ( Lescol - Sandoz), an HMG-CoA reductase inhibitor, was recently marketed in the USA for treatment of hypercholesterolemia. A synthetic mevalonolactone derivative, it is chemically distinct from previously available drugs in this class.
Issue 891 · March 5, 1993
Choice of Cholesterol-Lowering Drugs

Lowering elevated serum cholesterol concentrations can slow progression and sometimes cause regression of atherosclerotic lesions. Most authorities advise patients with high cholesterol concentrations to eat…

Med Lett Drugs Ther. 1993 Mar 5; 35(891):19-22
Lowering elevated serum cholesterol concentrations can slow progression and sometimes cause regression of atherosclerotic lesions. Most authorities advise patients with high cholesterol concentrations to eat less fat and less cholesterol and, when appropriate, to lose weight. If these measures do not lower serum lipids sufficiently, drugs are frequently added to the regimen. When drugs are discontinued, serum cholesterol concentrations generally return to pretreatment levels.
Issue 872 · June 12, 1992
Pravastatin, Simvastatin, and Lovastatin For Serum Cholesterol Concentrations

Pravastatin - Bristol-Myers Squibb) and simvastatin ( Zocor -Merck), two new inhibitors of cholesterol synthesis similar to lovastatin ( Mevacor - Merck), have now been marketed in the USA for treatment of…

Med Lett Drugs Ther. 1992 Jun 12; 34(872):57-8
Pravastatin - Bristol-Myers Squibb) and simvastatin ( Zocor -Merck), two new inhibitors of cholesterol synthesis similar to lovastatin ( Mevacor - Merck), have now been marketed in the USA for treatment of hypercholesterolemia. Lovastatin (Medical Letter, 29:99, 1987) is the most frequently prescribed of all cholesterol-lowering drugs in the USA. Pravastatin and simvastatin were previously reviewed in The Medical Letter when they became available in Canada (volume 33, page 18, 1991).
Issue 839 · March 8, 1991
A Subdermal Progestin Implant For Long-Term Contraception

The Norplant System (Wyeth-Ayerst) for subdermal delivery of the synthetic progestin levonorgestrel was recently approved by the US Food and Drug Administration for use as a long-term contraceptive.

Med Lett Drugs Ther. 1991 Mar 8; 33(839):17-8
The Norplant System (Wyeth-Ayerst) for subdermal delivery of the synthetic progestin levonorgestrel was recently approved by the US Food and Drug Administration for use as a long-term contraceptive.
Issue 839 · March 8, 1991
Pravastatin And Simvastatin for Hypercholesterolemia

Pravastatin ( Pravachol - Bristol-Myers Squibb) and simvastatin ( Zocor - Merck), two new inhibitors of cholesterol synthesis similar to lovastatin ( Mevacor - Merck), have been marketed in Canada and several…

Med Lett Drugs Ther. 1991 Mar 8; 33(839):18-20
Pravastatin ( Pravachol - Bristol-Myers Squibb) and simvastatin ( Zocor - Merck), two new inhibitors of cholesterol synthesis similar to lovastatin ( Mevacor - Merck), have been marketed in Canada and several European countries and may soon be available in the USA for treatment of high plasma cholesterol concentrations. Drugs already marketed here for this indication were recently reviewed in The Medical Letter (Volume 33, page 1, January 11, 1991).
Issue 835 · January 11, 1991
Choice Of Cholesterol-Lowering Drugs

Recent reports indicate that lowering elevated serum cholesterol concentrations not only decreases mortality from coronary artery disease, but may cause regression of atherosclerotic lesions (JP Kane et al,…

Med Lett Drugs Ther. 1991 Jan 11; 33(835):1-4
Recent reports indicate that lowering elevated serum cholesterol concentrations not only decreases mortality from coronary artery disease, but may cause regression of atherosclerotic lesions (JP Kane et al, JAMA, 264:3007, Dec 19, 1990). Most authorities advise patients with high cholesterol concentrations to eat less saturated and total fat and lose weight. If these measures do not lower serum lipids, drugs are frequently added to the regimen. When drugs are discontinued, serum cholesterol concentrations generally return to pretreatment levels.
Issue 780 · December 2, 1988
Oat Bran for Lowering Blood Lipids

Oat bran, the ground inner husk of the grain, has recently become popular as a dietary means of lowering blood lipids. It is available both separately and as a constituent of oatmeal, which is the ground…

Med Lett Drugs Ther. 1988 Dec 2; 30(780):111-2
Oat bran, the ground inner husk of the grain, has recently become popular as a dietary means of lowering blood lipids. It is available both separately and as a constituent of oatmeal, which is the ground product of the whole grain. Oat bran and oatmeal are available in various breakfast cereals and can also be used in baked goods, such as muffins or bread. Some of these sources are listed in the table on page 112.
Issue 774 · September 9, 1988
Choice of Cholesterol-Lowering Drugs

The recent surge of interest in lowering serum cholesterol concentrations has led to vigorous promotion of various hypocholesterolemic drugs in the USA. Since the risk of coronary heart disease is increased in…

Med Lett Drugs Ther. 1988 Sep 9; 30(774):85-8
The recent surge of interest in lowering serum cholesterol concentrations has led to vigorous promotion of various hypocholesterolemic drugs in the USA. Since the risk of coronary heart disease is increased in patients with high serum cholesterol concentrations, most authorities advise such patients to eat less fat and try to lose weight (The Expert Panel, Arch Intern Med, 148:36, 1988). When these measures fail, cholesterol-lowering drugs are frequently recommended.
Issue 773 · August 26, 1988
Ursodiol for Dissolving Cholesterol Gallstones

Ursodiol (ursodeoxycholic acid), a naturally occurring bile acid, will soon be marketed in the USA as (Ciba-Geigy), an oral drug for dissolution of gallbladder stones. The labeling for the drug, which has been…

Med Lett Drugs Ther. 1988 Aug 26; 30(773):81-2
Ursodiol (ursodeoxycholic acid), a naturally occurring bile acid, will soon be marketed in the USA as (Ciba-Geigy), an oral drug for dissolution of gallbladder stones. The labeling for the drug, which has been available in other countries for the past ten years, will restrict its use to dissolution of radiolucent, noncalcified gallbladder stones less than 20 mm in diameter in patients who have refused or are at increased risk from surgery.